Nasal pharmaceutical formulations and methods of using the same

A nasal spray formulation comprising:

• an aqueous suspension having about 0.005% to about 5% by weight fluticasone and having the following particle size distribution profile:
• (i) about 10% of the drug substance particles have a particle size of less than 0.90 microns;
• (ii) about 25% of the fluticasone particles have a particle size of less than 1.6 microns;
• (iii) about 50% of the fluticasone particles have a particle size of less than 3.2 microns;
• (iv) about 75% of the fluticasone particles have a particle size of less than 6.2 microns;
• and
• (v) about 90% of the fluticasone particles have a particle size of less than 10 microns.

A method of treating one or more symptoms of rhinitis in an individual, said method comprising the steps of applying to the individual's nasal mucosa a formulation comprising about 0.005% to about 5% by weight fluticasone having the following particle size distribution profile:

• (i) about 10% of the fluticasone particles have a particle size of less than 0.90 microns;
• (ii) about 25% of the fluticasone particles have a particle size of less than 1.6 microns;
• (iii) about 50% of the fluticasone particles have a particle size of less than 3.2 microns;
• (iv) about 75% of the fluticasone particles have a particle size of less than 6.2 microns;
• and
• (v) about 90% of the fluticasone particles have a particle size of less than 10.0 microns, and wherein the fluticasone is suitable for administration to an individual via intranasally.